REVIEW PAPER
Inherited glycosylphosphatidylinositol deficiency disorders: a new group of inherited metabolic disorders
 
More details
Hide details
1
Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology, Pomeranian Medical University in Szczecin, Poland
 
2
Department of Pediatric Neurology, Medical University of Silesia, Katowice, Poland
 
3
Department of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Poland
 
4
Department of Pediatrics Surgery, Oncology, Urology and Hand Surgery, Pomeranian Medical University in Szczecin, Poland
 
 
Submission date: 2024-04-25
 
 
Final revision date: 2024-06-26
 
 
Acceptance date: 2024-07-11
 
 
Publication date: 2024-12-30
 
 
Corresponding author
Michał Patalan
Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology, Pomeranian Medical University in Szczecin
 
 
Pediatr Pol 2024;99(4):329-334
 
KEYWORDS
TOPICS
ABSTRACT
Inherited glycosylphosphatidylinositol deficiency disorders (IGDs) are a group of rare congenital disorders of glycosylation with multisystemic involvement. The underlying cause is an abnormal structure of glycosylphosphatidylinositol, which plays a significant role in the attachment of proteins to the cellular membrane. These glycosylphosphatidylinositol-anchored proteins are an important part of receptors, function as hydrolytic enzymes, and play a crucial role in molecules adhesion, immune response, embryogenesis and neurogenesis. Patients present a variety of symptoms including developmental delay with intellectual disability, abnormalities of the central nervous, skeletal, circulatory, gastrointestinal, and urinary systems, facial dysmorphia as well as hearing and visual impairment. Elevated alkaline phosphatase is a characteristic biochemical feature. The current state of knowledge connects the highly differentiated course of clini­cal presentation with the heterogenic molecular background evaluated in the next-generation sequencing methods. We present a comprehensive review of the pathogenesis, clinical symptomatology and management options in IGDs.
REFERENCES (27)
1.
Carmody LC, Blau H, Danis D, et al. Significantly different clinical phenotypes associated with mutations in synthesis and transamidase+remodeling glycosylphosphatidylinositol (GPI)-anchor biosynthesis genes. Orphanet J Rare Dis 2020; 15: 40. DOI: 10.1186/s13023-020-1313-0.
 
2.
Bellai-Dussault K, Nguyen TTM, Baratang NV, et al. Clinical variability in inherited glycosylphosphatidylinositol deficiency disorders. Clin Genet 2019; 95: 112-121.
 
3.
Jezela-Stanek A, Ciara E, Piekutowska-Abramczuk D, et al. Congenital disorder of glycosylphosphatidylinositol (GPI)-anchor bio­synthesis – the phenotype of two patients with novel mutations in the PIGN and PGAP2 genes. Eur J Paediatr Neurol 2016; 20: 462-473.
 
4.
Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73: 703-711.
 
5.
Pagnamenta AT, Murakami Y, Taylor JM, et al. Analysis of exome data for 4293 trios suggests GPI-anchor biogenesis defects are a rare cause of developmental disorders. Eur J Hum Genet 2017; 25: 669-679.
 
6.
Kinoshita T. Biosynthesis and biology of mammalian GPI-anchored proteins. Open Biol 2020; 10: 190290. DOI: 10.1098/rsob.190290.
 
7.
Kinoshita T, Fujita M. Biosynthesis of GPI-anchored proteins: special emphasis on GPI lipid remodeling. J Lipid Res 2016; 57: 6-24.
 
8.
Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293: 633-640.
 
9.
Legan PK, Rau A, Keen JN, et al. The Mouse Tectorins: modular matrix proteins of the inner ear homologous to components of the sperm-egg adhesion system. J Biol Chem 1997; 272: 8791-8801.
 
10.
Wu T, Yin F, Guang S, et al. The glycosylphosphatidylinositol biosynthesis pathway in human diseases. Orphanet J Rare Dis 2020; 15: 129. DOI: 10.1186/s13023-020-01401-z.
 
11.
Paprocka J, Hutny M, Hofman J, et al. Spectrum of neurological symptoms in glycosylphosphatidylinositol biosynthesis defects: systematic review. Front Neurol 2021; 12: 758899. DOI: 10.3389/fneur.2021.758899.
 
12.
Knaus A, Pantel JT, Pendziwiat M, et al. Characterization of glycosylphosphatidylinositol biosynthesis defects by clinical features, flow cytometry, and automated image analysis. Genome Med 2018; 10: 3. DOI: 10.1186/s13073-017-0510-5.
 
13.
Sidpra J, Sudhakar S, Biswas A, et al. The clinical and genetic spectrum of inherited glycosylphosphatidylinositol deficiency disorders. Brain 2024; 147: 2775-2790.
 
14.
Bayat A, Aledo-Serrano A, Gil-Nagel A, et al. Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency: a cohort study. Dev Med Child Neurol 2022; 64: 789-798.
 
15.
Bayat A, Lindau T, Aledo-Serrano A, et al. GPI-anchoring disorders and the heart: is cardiomyopathy an overlooked feature? Clin Genet 2023; 104: 598-603.
 
16.
Marques-da-Silva D, Francisco R, Webster D, et al. Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature. J Inherit Metabolic Dis 2017; 40: 657-672.
 
17.
Pode-Shakked B, Heimer G, Vilboux T, et al. Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation. Mol Genet Metabolism 2019; 128: 151-161.
 
18.
Hutny M, Lipinski P, Jezela-Stanek A. Characteristics of neuroimaging and behavioural phenotype in Polish patients with PIGV-CDG – an observational study and literature review. Genes (Basel) 2023; 14: 1208. DOI: 10.3390/genes14061208.
 
19.
Knight Johnson A, Schaefer GB, Lee J, et al. Alu-mediated deletion of PIGL in a Patient with CHIME syndrome. Am J Med Genet A 2017; 173: 1378-1382.
 
20.
Kettwig M, Elpeleg O, Wegener E, et al. Compound heterozygous variants in PGAP1 causing severe psychomotor retardation, brain atrophy, recurrent apneas and delayed myelination: a case report and literature review. BMC Neurol 2016; 16: 74. DOI: 10.1186/s12883-016-0602-7.
 
21.
Nguyen TTM, Mahida S, Smith-Hicks C, et al. A PIGH mutation leading to GPI deficiency is associated with developmental delay and autism. Hum Mutat 2018; 39: 827-829.
 
22.
Loong L, Tardivo A, Knaus A, et al. Biallelic variants in PIGN cause Fryns syndrome, multiple congenital anomalies-hypotonia-seizures syndrome, and neurologic phenotypes: a genotype-phenotype correlation study. Genet Med 2023; 25: 37-48.
 
23.
Bukowska-Olech E, Glista F, Dinwiddie A, et al. Rare multiple congenital anomalies-hypotonia-seizures syndrome type 1 (MCAHS1) – the clinical and molecular summary. Eur J Med Genet 2023; 66: 104668. DOI: 10.1016/j.ejmg.2022.104668.
 
24.
Ng BG, Freeze HH. Human genetic disorders involving glycosyl­phosphatidylinositol (GPI) anchors and glycosphingolipids (GSL). J Inherit Metab Dis 2015; 38: 171-178.
 
25.
Bayat A, Knaus A, Pendziwiat M, et al. Lessons learned from 40 novel PIGA patients and a review of the literature. Epilepsia 2020; 61: 1142-1155.
 
26.
Almeida AM, Murakami Y, Baker A, et al. Targeted therapy for inherited GPI deficiency. N Engl J Med 2007; 356: 1641-1647.
 
27.
Tanigawa J, Nabatame S, Tominaga K, et al. High-dose pyridoxine treatment for inherited glycosylphosphatidylinositol deficiency. Brain Dev 2021; 43: 680-687.
 
Journals System - logo
Scroll to top